PSMA-targeted radiopharmaceutical clinical trials in the US

Now that the VISION trial of Lu-177-PSMA-617 is no longer recruiting, some patients are wondering if they can still get PSMA-targeted radiopharmaceuticals in the US, without traveling to Germany, Australia, India, etc. Here is a list of trials that are active, still open to recruitment, or will soon be recruiting. 

Unless otherwise noted, they are all for men who are: 

• metastatic
• castration-resistant 
• have had at least one taxane chemotherapy
• at least one of the advanced androgen receptor therapies (e.g., Zytiga, Xtandi, Erleada, or Nubeqa)
• no Xofigo
• PSMA-avid on a PSMA PET/CT scan

Links that have contact information are provided.

Radiopharmaceutical	Adjuvant drugs	Extra criteria	Recruitment status/ contact	Locations
Lu-177-PSMA-617	Zytiga, Xtandi, or Erleada	mHSPC	Begins 5/3/21	Not yet announced
Lu-177-PSMA-PNT2002		Progressed on one second-line hormonal. No chemo for CRPC	recruiting	Houston
Lu-177-PSMA-617		Chemo and immunotherapy naïve, failed one hormonal	Begins 4/30/21	Not yet announced
Lu-177-PSMA-617	Keytruda	No chemo since castration resistant	recruiting	UCSF
Lu-177-CTT1403		No Jevtana	recruiting	UCSF
Lu-177-PSMA-617			recruiting	•Weill Cornell •Tulane (not yet)
Th-227-Antibody (see article)			recruiting	• Royal Marsden (UK) • Finland • Tulane • MSK • Omaha, NE
Lu-177-J591	Ketoconazole	Prior RP or RT Castration-resistant Non-metastatic	recruiting	• Weill Cornell • USC • Georgetown • IU • U of Iowa • UPMC
Lu-177-PSMA-R2			recruiting	• Stanford • Yale • Tulane • Johns Hopkins • Mt Sinai • MD Anderson • U of Wisconsin • Phoenix
Ac-225-J591			recruiting	• Weill Cornell • Tulane
Ac-225-J591			recruiting	• Weill Cornell • Brooklyn Methodist
Lu-177-PSMA-617 (VISION)			Active, not recruiting	• 84 locations Results expected August 2020
I-131-1095-MIPS (see article)	Xtandi	Chemo naïve Failed Zytiga	Active, not recruiting	• 17 locations Results expected December 2021